Yahoo España Búsqueda web

Entrar

Search results

  1. br.investing.com › news › company-newsCognition Therapeutics para apresentar os resultados do estudo de...

    Hace 1 día · Enquanto a Cognition Therapeutics, Inc (NASDAQ: CGTX) se prepara para apresentar seus resultados do estudo de Fase 2 na Conferência Internacional da Alzheimer's Association, investidores e partes interessadas do setor estão monitorando de perto a saúde financeira e o desempenho do mercado da empresa. Aqui estão alguns dos principais ...

  2. es.investing.com › news › company-newsCognition Therapeutics presentará los resultados de un estudio...

    Hace 1 día · CGTX. 7,78%. PURCHASE, N.Y. - Cognition Therapeutics, Inc. (NASDAQ: CGTX), compañía biofarmacéutica en fase clínica, ha anunciado hoy que los resultados de su estudio de fase 2 del fármaco ...

  3. nl.investing.com › news › company-newsCognition Therapeutics presenteert onderzoeksresultaten naar...

    Hace 1 día · Cognition Therapeutics zal ook een stand hebben op de conferentie om meer informatie te geven over het programma voor de ziekte van Alzheimer en de hoofdkandidaat CT1812. Het bedrijf houdt zich bezig met de ontwikkeling van therapeutica voor degeneratieve aandoeningen van het centrale zenuwstelsel en het netvlies, met een pijplijn van sigma-2 receptormodulatoren.

  4. uk.investing.com › news › company-newsCognition Therapeutics to present Alzheimer's study findings

    Hace 1 día · Cognition Therapeutics will also host a booth at the conference to provide more information about its Alzheimer’s disease program and the lead candidate CT1812. The company is engaged in developing therapeutics targeting degenerative disorders of the central nervous system and retina, with a pipeline of sigma-2 receptor modulators.

  5. www.wtvr.com › politics › health-careFDA approves Alzheimer's drug that may slow memory decline in...

    Hace 1 día · The U.S. Food and Drug Administration has approved a new drug to treat Alzheimer's disease, and it's been shown to slow the decline in memory and cognition that patients have.

  6. it.investing.com › news › company-newsCognition Therapeutics presenterà i risultati dello studio sull...

    Hace 1 día · 11,98%. PURCHASE, N.Y. - Cognition Therapeutics, Inc. (NASDAQ: CGTX), azienda biofarmaceutica in fase clinica, ha annunciato oggi che i risultati dello studio di Fase 2 sul farmaco CT1812 saranno presentati all'Alzheimer's Association International Conference di Philadelphia, PA, in programma dal 28 luglio al 1° agosto 2024.

  7. uk.news.yahoo.com › healthy-diets-early-life-tied-144146107Healthy diets in early life tied to better cognition in old age -...

    Hace 1 día · Gabriela Galvin. Tue, 2 July 2024, 10:41 am GMT-4 · 2-min read. Healthy diets in early life tied to better cognition in old age - study. A healthy diet in childhood and middle age could reap major cognitive benefits later on, according to new research that spans nearly seven decades in the United Kingdom. The findings come from the 1946 ...